All In Biotech

Drug Trial Radar · NCT04532606

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Impact of Remimazolam Tosilate for General Anesthesia on Prognosis After Bladder Cancer Surgery: a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,128 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,128

Planned (sponsor's estimate)

Start

Feb 5, 2021

Primary completion

Oct 2025

Study completion Oct 2026

Sponsor

Lead sponsor
Peking University First HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Tsinghua Chang Gung Hospital; Navy General Hospital, Beijing; Guizhou Provincial People's Hospital; Jiangsu Provincial People's Hospital; Shanghai 10th People's Hospital
First posted
Aug 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.

Conditions

  • Benzodiazepines
  • Bladder Cancer
  • Delirium
  • Surgery
  • Cancer Recurrence

Interventions

  • RemimazolamDrug

    Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.

  • PropofolDrug

    Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of emergence delirium (early).Time frame: Up to 2 hours during the stay in post-anesthesia care unit after surgery.
  2. Recurrence-free survival (long-term).Time frame: Up to 3 years after surgery.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Chang Gung Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Sixth Medical Center of PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University First Hospital

    Beijin, Bejing, China · Recruiting

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China · Recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Shanghai 10th People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.